Peptide-targeted PEG-liposomes in anti-angiogenic therapy.
暂无分享，去创建一个
R. Schiffelers | G. Molema | G. Koning | R. Kok | G. Storm | A. P. Janssen | T. T. ten Hagen | A. J. Schraa | T. L. T. ten Hagen | Timo L.M. ten Hagen | Gert Storm | Grietje Molema
[1] A. Griffioen,et al. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. , 2000, Pharmacological reviews.
[2] C. Demangel,et al. Identification of a peptide blocking vascular endothelial growth factor (VEGF)‐mediated angiogenesis , 2000, The EMBO journal.
[3] D. Cheresh,et al. The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development. , 1999, The Journal of clinical investigation.
[4] G. Storm,et al. Immunoliposomes as Enzyme-Carriers (Immuno-Enzymosomes) for Antibody-Directed Enzyme Prodrug Therapy (ADEPT): Optimization of Prodrug Activating Capacity , 1996, Pharmaceutical Research.
[5] D. Cheresh,et al. An antagonist of integrin alpha v beta 3 prevents maturation of blood vessels during embryonic neovascularization. , 1995, Journal of cell science.
[6] D. Cheresh,et al. Requirement of vascular integrin alpha v beta 3 for angiogenesis. , 1994, Science.
[7] J. Gross,et al. A transparent access chamber for the rat dorsal skin fold. , 1979, Microvascular research.
[8] E Ruoslahti,et al. RGD and other recognition sequences for integrins. , 1996, Annual review of cell and developmental biology.